Phenibut
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Phenibut (4-amino-3-phenylbutanoic acid) is a synthetic depressant of the gabapentinoid class. It is closely related to baclofen, differing by a single atom on the phenyl ring.[1] It calms the brain by activating GABA receptors and suppressing calcium-channel signaling, producing its characteristic anxiolysis and sedation.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
baclofen, gabapentin, pregabalin +1 morebaclofen, gabapentin, pregabalin, benzodiazepines show less
Phenibut was synthesized in the Soviet Union in the early 1960s, designed to reduce anxiety without impairing mental function.[4] It entered clinical practice in Russia and neighboring countries and was carried in Soviet cosmonaut medical kits as a stress-reducing compound compatible with operational duty.[4] In Western countries it has no approved use and circulates online, though bans and restrictions are accumulating.[5]
Subjective effects include anxiolysis, euphoria, sociability, and sedation.[6] The experience is a warm, socially lubricating calm — less impairing than alcohol, with a clean sense of well-being at lower doses. Higher doses bring heavy sedation, motor impairment, and cognitive dulling; the slow onset of up to four hours regularly tempts premature redosing.
Phenibut produces rapid physical dependence — tolerance builds within days — though no confirmed fatalities from phenibut alone appear in published literature.[7][8] Doses commonly escalate far above therapeutic levels, and stopping abruptly can trigger delirium, hallucinations, and seizures.[9][10] No Western clinical trials exist — what is known comes from case reports and poison center surveillance.[5]
History[edit]
Discovery
Phenibut was first synthesized in the Soviet Union in the early 1960s by Professor Vsevolod Perekalin and his team.[4][5] The goal was a GABA structural analog that could cross the blood-brain barrier — GABA itself cannot — and reduce anxiety with less sedation than existing tranquilizers.[11] Adding a phenyl group to GABA's backbone gave the molecule the lipophilicity needed to reach the brain.[6]
Clinical adoption and cosmonaut use
Phenibut entered Soviet clinical practice in the 1960s and was eventually registered as Noofen in Russia, Ukraine, Belarus, Georgia, and Latvia.[6] Its inclusion in cosmonaut medical kits reflected a key advantage: it reduced stress without degrading cognitive or operational performance — something benzodiazepines could not offer.[4]
Western emergence and regulation
The first English-language pharmacological overview appeared in 2001[6] and dependence cases began surfacing in 2013.[9] US poison center calls rose substantially between 2009 and 2019.[12][13] Australia banned it in 2018,[14] and the FDA determined in 2023 that it does not qualify as a dietary ingredient.[15]
The name "phenibut" derives from phenyl + butanoic acid, with the middle syllable reflecting its GABA parentage. In Russian medicine it is classified as a "nootropic" — a term with broader clinical meaning in post-Soviet usage than in the West, where nootropic typically implies cognitive enhancement. Online communities often frame phenibut as a "social lubricant" or "confidence pill" set against alcohol — a framing that obscures its dependence potential.
Chemistry[edit]
Structural class
Phenibut (4-amino-3-phenylbutanoic acid) is a synthetic derivative of GABA — the brain's primary inhibitory neurotransmitter — belonging to the β-phenyl-GABA class.[6] A phenyl group added to GABA's backbone makes the molecule lipophilic enough to cross the blood-brain barrier, which GABA itself cannot do.[6]
Baclofen is the nearest structural relative, differing only by a chlorine atom on the ring; gabapentin and pregabalin share phenibut's calcium channel binding activity and are grouped with it as gabapentinoids.[6][16]
Molecular properties
| Molecular formula | C₁₀H₁₃NO₂ |
| Molecular weight | 179.22 g/mol |
Pharmacology[edit]
Mechanism of action
Phenibut acts on two targets. It activates GABA receptors — reducing neuronal excitability[17] — though with roughly 30 times less potency than baclofen.[1] It also binds calcium channels at the same site as gabapentin and pregabalin, suppressing neurotransmitter release through a second, independent pathway.[3][16]
Pharmacokinetics
Peak effects arrive 3–4 hours after ingestion[8] — an unusually slow onset that drives many accidental overdoses when a second dose is taken before the first takes hold. About two-thirds of a dose is excreted unchanged in urine;[8] how the rest is metabolized remains unclear, with contradictory data in the literature.[8]
Neuroscience[edit]
Where it acts
Phenibut suppresses brain excitability through two independent pathways. GABA receptor activation calms anxiety-relevant circuits — the amygdala, prefrontal cortex, and hippocampus.[17] Calcium channel binding reduces neurotransmitter release through a separate mechanism, contributing to pain suppression and the anxiolytic effects shared with gabapentin and pregabalin.[3]
Why it matters
This dual inhibition may explain why phenibut feels different from either baclofen or gabapentin alone. Additional activity in dopamine circuits may explain the euphoria and sociability reported at lower doses.[6]
Chronic use drives the brain to compensate by ramping up excitatory activity across both pathways. When phenibut stops abruptly, both systems rebound effect at once — producing delirium, seizures, and psychosis more severe than either mechanism would generate alone.[5]
How much of phenibut's anxiolytic effect comes from GABA receptors versus calcium channels remains unresolved — the studies needed to isolate each pathway have not been done. The dopaminergic activity reported in early studies[6] lacks characterization: which receptor, what binding affinity, and whether the effect is direct or indirect are all unknown.
Subjective Effects[edit]
Phenibut produces a distinctive warm calm — anxiety recedes, social ease rises, and the body settles without obvious impairment. The effect is less a high than a quieting: discomfort fades, conversation flows, and the world feels more manageable. At higher doses, that quiet calm tips into sedation and euphoria.
The closest comparisons are high-dose gabapentin and moderate-dose alcohol, but phenibut's anxiolysis tends to feel cleaner and last longer than either. Relative to baclofen, phenibut produces more noticeable euphoria and sociability — likely reflecting its additional mechanisms beyond basic GABA activation.
Effect Grid
At common doses (1000–2000 mg oral), the full anxiolytic and euphoriant profile emerges. Anxiety suppression is pronounced — social situations that would normally produce apprehension feel manageable or enjoyable. Euphoria ranges from a sustained warm contentment to a more overt emotional elevation. Sociability enhancement is marked, with increased empathy and desire for conversation.
Sedation becomes dose-dependent and noticeable, particularly at the upper end. Muscle relaxation is appreciable. Motor control may show subtle impairment — slight unsteadiness or reduced coordination. Sleep quality is typically enhanced if dosing allows effects to extend into the sleep window.
Functional impairment is moderate: complex tasks remain possible but reaction time and fine motor control are diminished. The full experience lasts 10–16 hours including residual effects, representing a significant time commitment.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Visual acuity suppression · Visual haze / noise · Visual processing suppression · Internal hallucinations
Internal hallucinations
Dizziness · Bodily heaviness · Insomnia · Physical fatigue · Tactile euphoria · Sexual arousal enhancement · Headache · Nausea · Body high · Brain zaps · Dry mouth · Sexual arousal suppression · Excessive sweating · Diarrhea · Dehydration sensation · Muscle tension · Pupil dilation · Temperature dysregulation · Heart rate perception changes · Nystagmus (eye wobbles) · Restlessness · Spontaneous body sensations · Stimulation · Tingling / electric sensations · Trembling · Appetite enhancement · Yawning · Increased urination · Abnormal heartbeat · Involuntary body movements · Vomiting
Physical fatigue · Tactile euphoria · Sexual arousal enhancement · Headache · Nausea · Body high · Brain zaps · Dry mouth · Sexual arousal suppression · Excessive sweating · Diarrhea · Dehydration sensation · Muscle tension · Pupil dilation · Heart rate perception changes · Nystagmus (eye wobbles) · Restlessness · Spontaneous body sensations · Stimulation · Tingling / electric sensations · Trembling · Appetite enhancement · Yawning · Increased urination · Abnormal heartbeat · Involuntary body movements · Vomiting
Analysis suppression · Thought deceleration · Cognitive dysphoria · Focus suppression · Information processing suppression · Memory suppression · Motivation enhancement · Focus enhancement · Confusion · Delusions of sobriety · Language suppression · Memory fragmentation · Thought disorganization · Amnesia · Delirium
Focus suppression · Information processing suppression · Memory suppression · Motivation enhancement · Focus enhancement · Confusion · Language suppression · Memory fragmentation · Thought disorganization · Amnesia · Delirium
Irritability · Empathy enhancement · Anhedonia · Emotional enhancement · Emotional lability · Emotional suppression
Emotional lability · Emotional suppression
Communication enhancement · Depersonalization · Communication suppression · Ego inflation · Sociability suppression · Derealization
Sociability suppression · Derealization
Timeline
First alerts emerge gradually — a subtle lightening of mood or faint reduction in baseline anxiety. The slow onset reflects phenibut's limited water solubility and 3–4 hour Tmax.
Anxiolysis becomes clearly perceptible. Social ease increases, mild euphoria surfaces, and muscle tension begins to release. Effects build slowly enough that the transition from onset to come-up is often imperceptible.
Maximum anxiolysis, euphoria, and sociability. Sedation is dose-dependent — mild warmth at common doses, pronounced drowsiness at strong doses. Muscle relaxation and subtle motor impairment are present.
Effects sustain at reduced intensity. Anxiolysis remains but euphoria fades. Sedation may increase as stimulating components recede.
Gradual return toward baseline. Residual sedation and muscle relaxation persist. Mood remains mildly elevated.
Residual calmness, mild fatigue, or slight cognitive blunting may persist for 6–24 hours after subjective effects resolve. Some users report improved sleep quality on the following night.
⚠ Do not drive or operate heavy machinery until at least 24 hours after dosing, as residual sedation and impaired reaction time may persist beyond the subjective experience.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- baclofen · gabapentin · pregabalin
Toxicity
Acute toxicity
No LD₅₀ data for phenibut exist in published English-language literature.safety citation needed The maximum reported surviving single oral dose is 100 g — in a monotherapy case, it produced neither respiratory depression nor severe intoxication.[8] No confirmed fatalities from phenibut alone appear in published Western literature as of 2024.[8]
The picture changes sharply in combination. Around half of US intoxication cases required intubation, primarily when phenibut was combined with opioids, benzodiazepines, or alcohol.[8] Overdose follows a CNS depression spectrum — drowsiness and unsteadiness progressing to unresponsiveness and coma; paradoxical agitation and acute psychosis have also been reported.[18][5]
Detection
Standard drug screens do not detect phenibut.[5][11] Identification requires specialized testing unavailable in most emergency departments, meaning clinicians may miss phenibut involvement in cases of unexplained sedation.
Psychological risks
At moderate doses, acute psychological distress is uncommon. The dominant risk is dependence and dose escalation, not acute toxicity.
High doses and withdrawal both carry serious psychological risk: paranoia, visual and auditory hallucinations, and delirium have all been reported.[18][10][5] Compulsive use is common: 73% of patients presenting with withdrawal had prior substance use disorder histories, and 60% had pre-existing anxiety or depression — pointing to self-medication as a primary driver of escalation.[19]
Tolerance and dependence
Tolerance develops within days of daily use.[7][9] Dose escalation is characteristic: patients presenting with withdrawal had taken a mean of 13.6 g/day — representing 7–50× escalation above the therapeutic range.[19]
Withdrawal can begin within 3–4 hours of the last dose in heavily dependent individuals.[9] Mild-to-moderate symptoms include anxiety, agitation, tremors, insomnia, nausea, rapid heart rate, and cognitive deficits.[20][19] Severe symptoms include delirium, hallucinations, psychosis, and seizures.[10][5] Acute withdrawal typically resolves over 1–2 weeks; after prolonged heavy use, symptoms can persist for up to 6 months.[1]
No standardized withdrawal treatment exists.[5] Medical approaches include baclofen taper,[9] benzodiazepines for acute agitation and seizure prevention, phenobarbital when seizure risk is elevated,[21][5] and ancillary agents such as gabapentin, pregabalin, or dexmedetomidine.[5] Seizures have occurred even during baclofen taper.[22]
Drug interactions
No controlled interaction studies have been published — all data come from case reports and mechanism-based inference.safety citation needed
The dominant risk is additive CNS and respiratory depression when combined with other depressants. Alcohol co-use extends and worsens withdrawal.[23] Opioids add respiratory depression through overlapping inhibitory pathways.[13][5] Benzodiazepines act on different GABA receptors than phenibut does, adding their own inhibitory layer; combined dependence produces a more complex withdrawal syndrome.[24] GHB/GBL, barbiturates, and muscle relaxants carry additive CNS depression risk.
Contraindications
Combining with CNS depressants — opioids, benzodiazepines, or alcohol — is the highest-risk context: most serious intoxications involve co-ingestion.[8][5]
Breathing difficulties: Phenibut may trigger respiratory failure in individuals with pre-existing respiratory disease or sleep apnea.[5][10]
History of substance use disorder: 73% of withdrawal cases had prior substance use disorder, indicating elevated vulnerability.[19]
Pre-existing anxiety or depression: 60% of withdrawal cases had comorbid anxiety or depression, suggesting a self-medication pathway to dependence.[19]
Daily or frequent use leads to rapid tolerance and physical dependence within days.[7]
Pregnancy and lactation: No human data exist on reproductive safety or neonatal withdrawal.safety citation needed
Harm Reduction[edit]
Forms & Identification
Phenibut is most commonly sold as a white crystalline powder (free acid or hydrochloride salt) or in capsules. Powder forms are hard to identify visually — phenibut is indistinguishable from many other white powders, and potency varies between batches and salt forms. A milligram-accurate scale is essential; volumetric scooping is unreliable.
No widely available reagent test reliably identifies phenibut. Confirming product identity requires a drug checking service using FTIR or GC-MS.
Guidelines
- Weigh doses with a milligram-accurate scale. Do not estimate by volume.
- Start at the lowest effective dose and wait a full 4–5 hours before considering any additional intake — the slow onset is not a sign of underdosing.
- Avoid daily use. Tolerance develops within days, and the path from daily dosing to physical dependence is rapid.
- Do not combine with alcohol, opioids, benzodiazepines, or other CNS depressants.
- Stay hydrated and eat before dosing — phenibut on an empty stomach may produce nausea.
- Inform a trusted person of what you have taken and when, especially if using alone.
- Keep a written log of use frequency and dose amounts. Escalation often occurs gradually and goes unnoticed without records.
Set & Setting
Phenibut's slow onset — 3–4 hours to peak — is the single most practically important feature for risk management. The impulse to redose because "nothing is happening" is the most common path to accidental overdose. A calm, familiar environment with a trusted companion reduces physical and psychological risk, particularly at higher doses where sedation and motor impairment can escalate rapidly.
Aftercare & integration. Recovery from a single use is typically straightforward — mild fatigue, grogginess, or low mood the following day are common. Adequate sleep, hydration, and light nutrition support recovery. Avoid redosing the next day to interrupt the tolerance cycle before it begins.
If phenibut was used to manage social anxiety or emotional distress, reflect on what drove the use. Journaling the experience — what felt better, what felt different, what the cost was — helps identify whether a pattern of self-medication is developing. If use is becoming regular, this is the point to intervene.
Recovery & Support
Phenibut dependence is a recognized medical condition, and withdrawal can be dangerous — do not attempt to stop abruptly after sustained daily use. Medical supervision is strongly recommended for anyone using daily for more than two weeks or at doses exceeding 2–3 g/day.
Baclofen-assisted taper under medical supervision is the most commonly documented approach. The process is gradual and may take weeks to months depending on dose and duration of use. Benzodiazepines or phenobarbital may be added for seizure prevention.
Support resources include addiction medicine specialists, SAMHSA's National Helpline (1-800-662-4357, US), and online communities where people share tapering experiences. If a doctor is unfamiliar with phenibut, directing them to published case reports on phenibut withdrawal management may facilitate appropriate care.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unresponsiveness, extremely slowed or stopped breathing, inability to be roused, or seizure activity are immediate emergencies. Paradoxical agitation with confusion and psychotic behavior also warrants emergency response. A person who is deeply sedated and cannot be woken should be treated as a medical emergency.
Immediate steps:
- Call emergency services immediately.
- Place the person in the recovery position (on their side) to prevent choking.
- Do not leave them alone. Monitor breathing continuously.
- Do not induce vomiting.
- If an opioid was also taken and naloxone is available, administer it — phenibut itself has no reversal agent, but naloxone can reverse opioid-related respiratory depression.
What to tell the dispatcher: Name the substance (phenibut), the estimated amount and time taken, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution when seeking help for a drug-related emergency.
Legal Status[edit]
Phenibut is a licensed prescription medicine in Russia and several former Soviet states, and unscheduled or increasingly restricted elsewhere — the WHO reviewed it in 2021 and recommended continued surveillance rather than international scheduling.[18]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled; not a dietary ingredient | FDA (2023) determined phenibut does not meet the definition of a dietary ingredient; products sold as supplements are misbranded. Legal to possess. DEA requested public comment on international scheduling (2021)[15][25] |
| United States (state) | Varies by state | Utah: Schedule I (2025). Alabama: Schedule II[26] |
| United Kingdom | Controlled under PSA 2016 | Psychoactive Substances Act 2016 prohibits supply and production. Personal possession not an offense under PSA[26] |
| Australia | Schedule 9 (prohibited) | Classified February 2018 following TGA review due to withdrawal and overdose risk. Importation, sale, and possession without authorization are criminal offenses[14] |
| Canada | Unscheduled | Available online. Health Canada does not classify phenibut as a natural health product. Unregulated[26] |
| Germany | Controlled under NPS Act | Production, possession, and trafficking illegal under New Psychoactive Substances Act[8] |
| France | Prohibited | Not legally available[26] |
| Italy | Controlled substance | Classified as controlled[26] |
| Hungary | Controlled substance | Classified as controlled[26] |
| Lithuania | Prohibited | Banned December 2019[26] |
| Russia, Ukraine, Belarus, Georgia | Licensed prescription medicine | Approved medical use since 1960s. Available as Noofen and other brands[4] |
| Latvia | Licensed prescription medicine | Registered pharmaceutical for anxiety, insomnia, PTSD[4] |
Legal status changes frequently. The information above reflects the situation as of 2024 and is not legal advice — verify current local laws before possession or purchase.
references
- [1]
- [2] ^Dambrova M, Zvejniece L, Liepinsh E, Cirule H, Zharkova O, Veinberg G, Kalvinsh I (2008) Comparative pharmacological activity of optical isomers of phenibut — European Journal of Pharmacology doi:10.1016/j.ejphar.2008.01.015
- [3] ^abcZvejniece L, Vavers E, Svalbe B, Veinberg G, Rizhanova K, Liepins V, Kalvinsh I, Dambrova M (2015) R-phenibut binds to the alpha2-delta subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects — Pharmacology, Biochemistry, and Behavior doi:10.1016/j.pbb.2015.07.014
- [4]
- [5]
- [6]